Pandemic influenza A H1N1 vaccines and narcolepsy: Vaccine safety surveillance in action

The Lancet Infectious Diseases

Volumn 14, Issue 3, 2014, Pages 227-238

  Barker, Charlotte I S ^a,b   Snape, Matthew D ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE DRUG REACTION REPORTING SYSTEMS; EPIDEMIOLOGICAL MONITORING; HUMANS; INCIDENCE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NARCOLEPSY; PANDEMICS; VACCINATION;

AS 03; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; UNCLASSIFIED DRUG;

2009 H1N1 INFLUENZA; ADVERSE DRUG REACTION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GLOBAL ADVISORY COMMITTEE ON VACCINE SAFETY; HEALTH PRACTITIONER; HUMAN; INCIDENCE; INFECTION PREVENTION; INFLUENZA A (H1N1); INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INTERPERSONAL COMMUNICATION; LICENSING; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NARCOLEPSY; PANDEMIC INFLUENZA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL DETECTION;

EID: 84894334125     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70238-X     Document Type: Review

References (102)

1. H5N1 avian influenza: timeline of major events WHO, (accessed April 30, 2012). http://www.who.int/influenza/human_animal_interface/H5N1_avian_influenza_update200412.pdf.
2. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012, 12:687-695.
3. Robertson JS, Inglis SC Prospects for controlling future pandemics of influenza. Virus Res 2011, 162:39-46.
4. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (Revision); 18 Dec 2008. EMEA/CPMP/VEG/4717/2003- Rev.1 European Medicines Agency, (accessed July 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003869.pdf.
5. First pre-pandemic vaccine approved to help protect against pandemic influenza: GSK's Prepandrix(TM) obtains first EU authorisation for a pre-pandemic H5N1 vaccine. Vol. 2009 GlaxoSmithKline, (accessed Oct 27, 2013). http://www.gsk.com/media/press-releases/2008/first-pre-pandemic-vaccine-approved-to-help-protect-against-pandemic-influenza.html.
6. CHMP Assessment Report for Pandemrix. June 2008. EMA Evaluation of Medicines for Human Use. Doc Ref: EMEA/285631/2008 European Medicines Agency, (accessed July 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000832/WC500038124.pdf.
7. European Medicines Agency recommends authorisation of two vaccines for influenza pandemic (H1N1) 2009. EMA press release (2009) European Medicines Agency, (accessed July 31, 2012). http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2009/11/news_detail_000038.jsp&mid=WC0b01ac058004d5c1.
8. The MPA investigates reports of narcolepsy in patients vaccinated with Pandemrix Medical Products Agency; Sweden, (accessed July 31, 2012). http://www.lakemedelsverket.se/english/All-news/NYHETER-2010/The-MPA-investigates-reports-of-narcolepsy-in-patients-vaccinated-with-Pandemrix/.
9. Questions and answers on the review of Pandemrix influenza vaccine (H1N1) (split virion, inactivated, adjuvanted) A/California/7/2009 (H1N1)v like strain (X-179A). Outcome of a procedure under Article 20 of Regulation (EC) No 726/2004. EMA/CHMP/562838/2011 corr*1. EMEA/H/C/832/A-20/045 European Medicines Agency, (accessed Jan 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2011/07/WC500109183.pdf.
10. Kornum BR, Faraco J, Mignot E Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 2011, 21:897-903.
11. Stores G Recognition and management of narcolepsy. Arch Dis Child 1999, 81:519-524.
12. European Medicines Agency starts review of Pandemrix. EMA Press Release 27 August 2010 (EMA/543435/2010) European Medicines Agency (EMA), (accessed Jan 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2010/08/WC500096005.pdf.
13. Guideline on adjuvants in vaccines for human use. EMEA/CHMP/VEG/134716/2004 European Medicines Agency, Committee for Medicinal Products for Human UseCommittee for Medicinal Products for Human Use, (accessed March 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf.
14. Influenza pandemic preparedness and response. Report by the Secretariat. Geneva: January 2005: Report no: EB115/44 WHO, (accessed Oct 27, 2012). http://www.wpro.who.int/emerging_diseases/documents/docs/B115_44en.pdf.
15. Scheifele DW, Ward BJ, Dionne M, et al. Evaluation of adjuvanted pandemic H1N1(2009) influenza vaccine after one and two doses in young children. Pediatr Infect Dis J 2011, 30:402-407.
16. O'Hagan DT, Tsai T, Reed S Emulsion-based adjuvants for improved influenza vaccines. Influenza vaccines for the future 2010, 327-357. Springer, Basel. 2nd ed. G.D. Giudice, R. Rappuoli (Eds.).
17. Hanquet G, Van Damme P, Brasseur D, et al. Lessons learnt from pandemic A (H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010). Vaccine 2011, 29:370-377.
18. Pandemic influenza A(H1N1)v vaccines authorised via the core dossier procedure. Explanatory note on scientific considerations regarding the licensing of pandemic A(H1N1)v vaccines. EMEA/608259/2009 rev European Medicines Agency, (accessed March 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500007567.pdf.
19. Vesikari T, Karvonen A, Tilman S, et al. Immunogenicity and safety of MF59-adjuvanted H5N1 influenza vaccine from infancy to adolescence. Pediatrics 2010, 126:e762-e770.
20. Walker WT, Faust SN Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev Vaccines 2010, 9:1385-1398.
21. Chu DW, Hwang SJ, Lim FS, et al. Immunogenicity and tolerability of an AS03(A)-adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009, 27:7428-7435.
22. Rumke HC, Bayas JM, de Juanes JR, et al. Safety and reactogenicity profile of an adjuvanted H5N1 pandemic candidate vaccine in adults within a phase III safety trial. Vaccine 2008, 26:2378-2388.
23. Langley JM, Frenette L, Ferguson L, et al. Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults. J Infect Dis 2010, 201:1644-1653.
24. Pandemrix. Summary of product characteristics, approved by the European Commission on 22 December 2009. GlaxoSmithKline, Germany European Medicines Agency, (accessed March 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000832/WC500038121.pdf.
25. Arepanrix Summary of Product Characteristics European Medicines Agency. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001201/WC500089737.pdf.
26. Wijnans L, de Bie S, Dieleman J, Bonhoeffer J, Sturkenboom M Safety of pandemic H1N1 vaccines in children and adolescents. Vaccine 2011, 29:7559-7571.
27. Vaccines and Related Biological Products Advisory Committee (VRBPAC): briefing document. Influenza A (H5N1) virus monovalent vaccine, adjuvanted US Food and Drug Administration, (accessed March 19, 2012). http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/bloodvaccinesandotherbiologics/vaccinesandrelatedbiologicalproductsadvisorycommittee/ucm333630.pdf.
28. Vaccines and Related Biological Products Advisory Committee Meeting. FDA Briefing Document. Influenza A (H5N1) virus monovalent vaccine, adjuvanted US Food and Drug Administration, (accessed March 19, 2013). http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM327561.pdf.
29. Association of receipt of Pandemrix™ and narcolepsy in children and adolescents in the UK (England) European Centre for Disease Prevention and Control (ECDC): scientific advice, (accessed March 31, 2013). http://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1312&RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews.
30. Butler D Regulators face tough flu-jab choices. Nature 2009, 460:446.
31. Pollack A Benefit and Doubt in Vaccine Additive. The New York Times (USA) (accessed March 31, 2012). http://www.nytimes.com/2009/09/22/health/22vacc.html?_r=1&pagewanted=all.
32. Thompson WW, Price C, Goodson B, et al. Early thimerosal exposure and neuropsychological outcomes at 7 to 10 years. N Engl J Med 2007, 357:1281-1292.
33. The importance of pharmacovigilance. Safety monitoring of medicinal products WHO, (accessed July 31, 2012). http://www.who.int/medicines/publications/drugalerts/Alert_124_AH1N1.PDF.
34. Lopalco PL, Johansen K, Ciancio B, De Carvalho Gomes H, Kramarz P, Giesecke J Monitoring and assessing vaccine safety: a European perspective. Expert Rev Vaccines 2010, 9:371-380.
35. Definition and application of terms for vaccine pharmacovigilance. Report of CIOMS/WHO Working Group on Vaccine Pharmacovigilance Council for International Organizations of Medical Sciences (CIOMS) 2012, (accessed March 31, 2012). http://whqlibdoc.who.int/publications/2012/9789290360834_eng.pdf.
36. Vaccine safety basics e-learning course WHO, (accessed Jan 31, 2012). http://www.vaccine-safety-training.org/adverse-events-classification.html.
37. Hasford J, Goettler A, Munter KH, Muller-Oerlinghausen B Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions. J of ClinEpidemiol 2002, 55:945-950.
38. Hazell L, Shakir SA Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006, 29:385-396.
39. National competent authorities (human) European Medicines Agency, (accessed March 31, 2013). http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/general/general_content_000155.jsp.
40. Vaccine Adverse Event Reporting System Centers for Disease Control and Prevention, Food and Drug AdministrationFood and Drug Administration, (accessed Jan 31, 2012). http://vaers.hhs.gov/index.
41. New Zealand Medsafe, (accessed March 19, 2013). http://www.medsafe.govt.nz/regulatory/pharmacovigilance.asp.
42. Health Canada, (accessed March 19, 2013). http://www.hc-sc.gc.ca.
43. Therapeutic Goods Administration, (accessed March 19, 2013). http://www.tga.gov.au/.
44. Hauben M, Aronson JK Defining 'signal' and its subtypes in pharmacovigilance based on a systematic review of previous definitions. Drug Saf 2009, 32:99-110.
45. Causality assessment of adverse events following immunization. Wkly Epidemiol Rec 2001, 76:85-89. Global Advisory Committee on Vaccine Safety.
46. Labadie J Preparing for Influenza pandemic. Uppsala reports (UR47) October 2009 (p10-11) (accessed July 31, 2012). http://who-umc.org/graphics/24353.pdf.
47. PaniFlow The Uppsala Monitoring Centre (WHO International Drug Monitoring Programme), (accessed July 31, 2012). http://who-umc.org/dynpage.aspx?id=98097&mn1=7347&mn2=7252&mn3=7254&mn4=7335.
48. Information Exchange System; Alert No. 124 (08 October 2009). A/H1N1 vaccination safety: new safety surveillance tool available. (Reference QSM/MC/IEA.124) WHO, (accessed July 31, 2012). http://www.who.int/medicines/publications/drugalerts/Alert_124_AH1N1.PDF.
49. Lehmann HC, Hartung HP, Kieseier BC, Hughes RA Guillain-Barre syndrome after exposure to influenza virus. Lancet Infect Dis 2010, 10:643-651.
50. ECDC - VAESCO investigation into narcolepsy European Centre for Disease Prevention and Control (ECDC): scientific advice, (accessed Feb 29, 2012). http://ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?List=a3216f4c-f040-4f51-9f77-a96046dbfd72&ID=457&Web=0be238ef-4498-4962-8826-2e082a1f1639.
51. National Institute for Health and Welfare recommends discontinuation of Pandemrix vaccinations (Aug 25, 2010) National Institute for Health and Welfare (THL); Finland, (accessed July 31, 2012). http://www.thl.fi/en_US/web/en/pressrelease?id=22930.
52. Reports of cases of narcolepsy and cataplexy in children and adolescents in Finland, Iceland, and Sweden (Mar 2, 2011) European Centre for Disease Prevention and Control (ECDC): Scientific advice, (accessed July 31, 2012). http://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1028&RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews.
53. Approaches to investigate a possible relationship between reported cases of narcolepsy and vaccination with Pandemrix (Sept 6, 2010) Medical Products Agency (Sweden), (accessed Feb 29, 2012). http://www.lakemedelsverket.se/upload/nyheter/2010/2010-09-06_pandemrix-narcolepsy-investigation-MPA.pdf.
54. Kansallisen narkolepsiatyöryhmän loppuraportti 31.8.2011 (Finnish National Narcolepsy Task Force's final report) National Institute for Health and Welfare (THL; Finland), (accessed Feb 29, 2012). http://www.thl.fi/thl-client/pdfs/c02a3788-a691-47a4-bca8-5161b6cff077.
55. Partinen M, Saarenpaa-Heikkila O, Ilveskoski I, et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS One 2012, 7:e33723.
56. Finnish National Narcolepsy Task Force's final report published (7 September 2011) WHO Regional Office for Europe, Vaccines and ImmunizationVaccines and Immunization, NewsNews, (accessed July 31, 2012). http://www.euro.who.int/en/health-topics/disease-prevention/vaccines-and-immunization/news/news/2011/09/finnish-national-narcolepsy-task-forces-final-report-published.
57. Nohynek H, Jokinen J, Partinen M, et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7:e33536.
58. Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations-results of a case inventory study by the MPA in Sweden during Medical Products Agency; Sweden, (accessed Feb 29, 2012). http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf.
59. Investigation of an increase in the incidence of narcolepsy in children and adolescents in 2009 and 2010: final report of national narcolepsy study steering committee Department of Health, Ireland, (accessed July 31, 2012). http://www.dohc.ie/publications/pdf/Final_Report_of_National_Narcolepsy_Study_Steering_Committee.pdf?direct=1.
60. Overview of Dutch cases of narcolepsy associated with pandemic influenza vaccine (Pandemrix).) Netherlands Pharmacovigilance Centre Lareb, (accessed July 31, 2013). http://www.lareb.nl/Signalen/kwb_2011_3_pande.
61. Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescents European Centre for Disease Prevention and Control (ECDC): scientific advice, (accessed July 31, 2012). http://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1161.
62. Interim Report of the National Narcolepsy Task Force National Institute for Health and Welfare (THL); Finland, (accessed July 31, 2012). http://www.thl.fi/thl-client/pdfs/dce182fb-651e-48a1-b018-3f774d6d1875.
63. European Medicines Agency recommends restricting use of Pandemrix. EMA Press Release. July 27, 2011. EMA/CHMP/568830/2011 European Medicines Agency (EMA), (accessed Jan 31, 2012). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/07/WC500109182.pdf.
64. Miller E, Andrews N, Stellitano L, et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 2013, 346:f794.
65. Heier MS, Gautvik KM, Wannag E, et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep Med 2013, 14:867-871.
66. Dauvilliers Y, Arnulf I, Lecendreux M, et al. Increased risk of narcolepsy in children and adults after pandemic H1N1 vaccination in France. Brain 2013, 136:2486-2496. Narcoflu-VF study group.
67. ECDC Technical Report: Narcolepsy in association with pandemic influenza vaccination: a multi-country European epidemiological investigation European Centre for Disease Prevention and Control, (accessed March 19, 2013). http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf.
68. ECDC Technical Report: Narcolepsy in association with pandemic influenza vaccination: a multi-country European epidemiological investigation European Centre for Disease Prevention and Control, (accessed March 19, 2013). http://www.ecdc.europa.eu/en/publications/Publications/Vaesco%20in%20brief%20final.pdf.
69. Wijnans L, Lecomte C, de Vries C, et al. The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine 2013, 31:1246-1254.
70. Epidemiological report of pandemic (H1N1) 2009 in the UK; April 2009 - May 2010. (Updated September 2010) Health Protection Agency, (accessed July 31, 2012). http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1284475321350.
71. Dauvilliers Y, Montplaisir J, Cohen V, et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33:1428-1430.
72. Pandemrix suspension and for emulsion for injection: Summary of Product Characteristics Electronic Medicines Compendium (eMC), (accessed March 19, 2013). http://www.medicines.org.uk/emc/medicine/22352/SPC/.
73. Assessment report: immunological differences of pandemic vaccines (review of hypothesis on Pandemrix and development of narcolepsy). 29 October 2012. EMA/687578/2012 European Medicines Agency (EMA), (accessed March 19, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Report/2012/11/WC500134716.pdf.
74. Montastruc JL, Durrieu G, Rascol O Pandemrix degrees, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2011, 29:2010.
75. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann of Neurol 2011, 70:410-417.
76. Tsai TF, Crucitti A, Nacci P, et al. Explorations of clinical trials and pharmacovigilance databases of MF59(R)-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011, 43:702-706.
77. Lee GM, Greene SK, Weintraub ES, et al. H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. Am J Prev Med 2011, 41:121-128.
78. Choe YJ, Bae GR, Lee DH No association between influenza A(H1N1)pdm09 vaccination and narcolepsy in South Korea: an ecological study. Vaccine 2012, 30:7439-7442.
79. Association between Pandemrix and narcolepsy confirmed among Finnish children and adolescents. (1 Sep 2011) National Institute for Health and Welfare (THL; Finland), (accessed July 31, 2012). http://www.thl.fi/en_US/web/en/pressrelease?id=26352.
80. Waddington CS, Walker WT, Oeser C, et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 2010, 340:c2649.
81. The MPA initiates research on vaccine safety and narcolepsy Medical Products Agency; Sweden, (accessed Feb 29, 2013). http://www.lakemedelsverket.se/english/All-news/NYHETER-2012/The-MPA-initiates-research-on-vaccine-safety-and-narcolepsy/.
82. Black S, Eskola J, Siegrist CA, et al. Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccines. Lancet 2009, 374:2115-2122.
83. Association of receipt of Pandemrix and narcolepsy in children and adolescents in the UK (England). Table 1. Examples of difficulties encountered investigating the possible relationship between Pandemrix™ and narcolepsy European Centre for Disease Prevention and Control (ECDC): Scientific advice, (accessed March 31, 2013). http://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1312&RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews.
84. UMC update on pandemic influenza vaccine safety monitoring no 5 The Uppsala Monitoring Centre (WHO International Drug Monitoring Programme), (accessed March 31, 2013). http://who-umc.org/graphics/24691.pdf.
85. Association of childhood narcolepsy and cataplexy and receipt of a pandemic influenza vaccine in Finland in 2009-10. First papers in a peer review journal European Centre for Disease Prevention and Control (ECDC): Scientific advice, (accessed March 30, 2012). http://ecdc.europa.eu/en/activities/sciadvice/Lists/ECDC%20Reviews/ECDC_DispForm.aspx?List=512ff74f-77d4-4ad8-b6d6-bf0f23083f30&ID=1264&RootFolder=%2Fen%2Factivities%2Fsciadvice%2FLists%2FECDC%20Reviews.
86. New pharmacovigilance legislation, July 2012. (Last updated Dec 12, 2012) Medicines and Healthcare products Regulatory Agency (MHRA), (accessed March 19, 2012). http://www.mhra.gov.uk/Howweregulate/Medicines/Pharmacovigilancelegislation/index.htm.
87. ECDC Technical Report: Narcolepsy in association with pandemic influenza vaccination: A multi-country European epidemiological investigation. Annex 1 Country-specific comments and disclaimers. p 155-56 European Centre for Disease Prevention and Control, (accessed March 19, 2012). http://www.ecdc.europa.eu/en/publications/publications/vaesco%20report%20final%20with%20cover.pdf.
88. Global Advisory Committee on Vaccine Safety, report of meeting held 7-8 December 2011. Safety of influenza A(H1N1)pdm09 vaccines WHO, (accessed March 31, 2013). http://www.who.int/vaccine_safety/committee/reports/Dec_2011/en/index.html.
89. Global Advisory Committee on Vaccine Safety, report of meeting held 5 to 6 December 2012. Pandemic Influenza vaccines WHO, (accessed March 31, 2013). http://www.who.int/vaccine_safety/committee/reports/Dec_2012/en/index.html.
90. Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis and pervasive developmental disorder in children. Lancet 2010, 375:445.
91. Elliman DA, Bedford HE MMR vaccine-worries are not justified. Arch Dis Child 2001, 85:271-274.
92. Bedford HE, Elliman DA MMR vaccine and autism. BMJ 2010, 340:c655.
93. FAQs about hepatitis B vaccine (Hep B) and multiple sclerosis Centers for Disease Control and Prevention, (accessed March 19, 2013). http://www.cdc.gov/vaccinesafety/Vaccines/multiplesclerosis_and_hep_b.html.
94. Caplan AL Duty to warn? The ethics of disclosing information about possible risks associated with H1N1 vaccination. Sleep 2010, 33:1426-1427.
95. Press release. European Medicines Agency recommends interim measures for Pandemrix. April 15, 2011. EMA/CHMP/297822/2011 European Medicines Agency, (accessed March 31, 2013). http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2011/04/WC500105278.pdf.
96. Amended Letter. The influenza immunisation programme 2010/11 Department of Health, (accessed March 19, 2013). http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_116943.pdf.
97. Completion of safety surveillance of pandemic influenza vaccines with the PaniFlow online system. Communication to healthcare professionals Swissmedic: Swiss Agency for Therapeutic Products, (accessed March 31, 2013). http://www.swissmedic.ch/aktuell/00003/01237/index.html?lang=en.
98. Sachedina N, Donaldson LJ Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010, 376:1846-1852.
99. Updated CDC Estimates of 2009 H1N1 Influenza Cases, Hospitalizations and Deaths in the United States, April 2009-April 10, 2010 Centers for Disease Control and Prevention, (accessed July 31, 2012). http://www.cdc.gov/h1n1flu/estimates_2009_h1n1.htm/pdf/Exact%20Numbers_AprilN.pdf.
100. Pebody RG, Andrews N, Fleming DM, et al. Age-specific vaccine effectiveness of seasonal 2010/2011 and pandemic influenza A(H1N1) 2009 vaccines in preventing influenza in the United Kingdom. Epidemiol Infect 2012, 13:1-11.
101. FDA panel supports H5N1 adjuvant vaccine Medscape Medical News, (accessed March 19, 2013). http://www.medscape.com/viewarticle/774695.
102. Eichler HG, Oye K, Baird LG, et al. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012, 91:426-437.